Sign in
CompletedPhase 3

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2)

Key facts

Who runs it
Keymed Biosciences Co.Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
180 people enrolled
Started
9 Aug 2022
Ended
25 Jun 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CM310
  • Placebo
Record updated
8 November 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • with chronic rhinosinusitis with nasal polyposis (CRSwNP)
  • Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity
  • NCS score of 2 or 3 at screening period, and at least 2 at baseline
  • Contraception

Who cannot take part

  • Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy)
  • Vaccination with live attenuated vaccine within 12 weeks before randomization or during the planned study period
  • With malignant or benign tumor of nasal cavity
  • Participated and any studies of CM310

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM310, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM310 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

The 2 groups in the trial

  • CM310Treatment being tested

    CM310 300mg is given subcutaneously (SC) every two weeks

    Treatment: Placebo

  • PlaceboPlacebo, for comparison

    Placebo is given subcutaneously (SC) every two weeks

    Treatment: CM310

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis
Publications
Record updated
8 November 2024